Financial Position - As of December 31, 2024, the company had cash and cash equivalents of $191.7 million, short-term deposits of $153.7 million, and short-term investments in marketable securities of $101.8 million[321]. - As of December 31, 2024, no credit losses have been recorded on the company's marketable securities investments[343]. Foreign Exchange Risk - A hypothetical 10% change in foreign currency exchange rates would have impacted the company's results of operations by $9.5 million and $8.3 million for the years ended December 31, 2024 and 2023, respectively[318]. - A 10% increase or decrease in current exchange rates would have affected the company's cash, cash equivalents, restricted cash, and short-term investment balances by $2.6 million and $3.1 million as of December 31, 2024 and 2023, respectively[320]. - The company has established a hedging program to reduce the impact of foreign exchange risks associated with forecasted future cash flows[318]. Corporate Governance and Management - The company is subject to various corporate governance requirements under the Companies Law, including the appointment of external directors[469]. - The board of directors consists of no less than three and no more than eleven directors, divided into three classes with staggered three-year terms[472]. - The company has a "foreign private issuer exemption" allowing it to comply with Israeli corporate governance practices instead of Nasdaq rules[470]. - The board of directors has determined that all directors, except Mr. Hogan, are independent as defined by Nasdaq corporate governance rules[479]. - The external directors were initially elected on November 29, 2021, and re-elected for a second three-year term on September 17, 2024[482]. - The lead independent director is responsible for presiding over meetings when the chairperson is absent and serving as a liaison between the chairperson and independent directors[499]. - The board of directors has adopted corporate governance guidelines to ensure compliance with applicable laws and regulations[498]. - The board of directors has established a compensation committee charter aligned with Nasdaq corporate governance rules[515]. Executive Compensation - The aggregate compensation for Cellebrite's executive officers and directors for the year ended December 31, 2024, was approximately $16.6 million, including $0.5 million for pension and similar benefits[375]. - Compensation expenses for the five highest-paid executives in 2024 included $150,000 for Thomas E. Hogan, $499,000 for former CEO Yossi Carmil, and $1,445,000 in equity-based compensation for Yossi Carmil[376]. - Non-employee directors receive an annual retainer of $60,000, with expert external directors receiving $75,000[379]. - The executive chairman's fixed annual service fee is $150,000, with a maximum annual bonus of $250,000 based on performance targets[381]. - An external director's compensation is determined prior to appointment and cannot be changed during their term, with certain exceptions[490]. Stock Options and Equity Plans - A total of 1,128,255 Options, PSUs, and RSUs were granted to executive officers and directors under equity incentive plans during 2024[375]. - As of December 31, 2024, there were options to purchase 1,806,335 Ordinary Shares outstanding under the 2008 Share Option Plan[388]. - As of December 31, 2024, there were options outstanding to purchase 4,313,566 Ordinary Shares under the 2019 Option Plan[403]. - The 2019 Option Plan allows for options to be granted under various tax regimes, including Section 102 of the Israeli Income Tax Ordinance[407]. - The 2019 Option Plan provides for a vesting schedule over a 4-year period, with one quarter vesting on the first anniversary and the remainder vesting quarterly thereafter[411]. - The 2021 Plan was adopted to incentivize employees and promote the success of the Company's business[437]. - The maximum number of shares initially available for issuance under the ESPP was 1,871,687 shares, equal to 1% of the outstanding shares immediately after the closing of the Merger[456]. - The maximum number of Ordinary Shares available for issuance under the 2021 Plan is equal to 18,716,872 shares, which is 10% of the outstanding shares immediately after the closing of the Merger[438]. Risk Factors - Inflationary factors may adversely affect the company's operating results, particularly if selling prices do not increase in line with rising costs[322]. Management Team - The Chief Financial Officer has been with the Company since May 2014, bringing extensive experience from previous roles in finance and management[355]. - The Chief Revenue Officer joined the Company in November 2023, previously serving as CRO at CSS LLC and Juniper Networks, with over 25 years of sales and management experience[359]. - The Chief Marketing Officer, who joined in March 2024, has over 25 years of technology sales and marketing leadership experience, previously serving in senior roles at Coherent Inc., Imperva, and HP[360]. - The Company’s Chairman of the Board has been in position since December 2024, previously serving as CEO of TWC Tech Holdings II, LLC, and has extensive experience in private equity and technology[363]. - The Company’s external director has been in position since November 2021, with a background in economics and previous roles including Deputy Governor of the Bank of Israel[364]. - The Company’s Lead Independent Director has been in position since January 2025, with a distinguished career including leadership roles at VCE, First Data Corporation, and MCI[365]. - The Chief Products & Technologies Officer has been with the Company since July 2020, previously serving as COO at Verbit.ai and holding key positions at HP Software[357]. - The Company has a diverse board of directors with extensive experience in technology, finance, and management, enhancing its strategic direction[363][364][365]. Shareholder Approval and Governance - The approval of at least 65% of the total voting power of shareholders is required to remove any directors, excluding external directors[478]. - The audit committee must consist of a majority of unaffiliated directors, ensuring compliance with the Companies Law[501]. - The compensation committee must be comprised of at least three directors, including all external directors, who must constitute a majority of the committee[509]. - Each member of the compensation committee must be independent under Nasdaq rules and the Exchange Act[510]. - The audit committee oversees the independent registered public accounting firm and recommends engagement, compensation, or termination[506]. - The compensation committee is responsible for approving the compensation policy for office holders and reviewing its implementation[512]. - The total number of shares voting against the compensation policy from non-controlling shareholders must not exceed 2%[516].

Group 1 - Cellebrite DI Ltd. (CLBT) has experienced a significant decline of 17.6% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for CLBT is currently at 28.57, suggesting that the heavy selling pressure may be exhausting itself [5] - There is strong consensus among Wall Street analysts that CLBT will report better earnings than previously predicted, with a 10.2% increase in the consensus EPS estimate over the last 30 days [6] Group 2 - CLBT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [7]

Core Insights - Cellebrite (CLBT) is identified as a significant player in the digital forensics sector, particularly for law enforcement applications [1] - The discussion includes evaluations of Cellebrite's growth potential, management effectiveness, and financial performance, which are crucial for investment decisions [1] Company Overview - Cellebrite specializes in digital forensics, providing tools and solutions for law enforcement agencies [1] - The company is positioned to benefit from increasing demand for digital evidence in criminal investigations [1] Financial Performance - Insights into Cellebrite's financials are provided, indicating areas of strength and potential growth [1] - The stock price mentioned is reflective of the market conditions as of January 15, 2025, with a noted decline of 5.53% [1]

Financial Data and Key Metrics Changes - Cellebrite achieved a full year 2024 revenue of $401.2 million, representing a 23% increase year-over-year, driven by a 26% increase in subscription software revenue [47][52] - The company reported a 25% year-over-year growth in Annual Recurring Revenue (ARR) to $396 million, with a gross retention rate of approximately 92% [41][42] - Adjusted EBITDA for 2024 was $99.4 million, a 60% increase from the previous year, resulting in a margin of 24.8%, up from 19.1% in 2023 [51][59] Business Line Data and Key Metrics Changes - The Inseyets product suite was the largest contributor to ARR growth, with significant demand for advanced smartphone access [44][46] - ARR for Guardian and Pathfinder solutions grew nearly 50% in 2024, with Guardian ARR experiencing triple-digit percentage growth year-over-year [28][46] - The company reported a 28% increase in subscription services in Q4 2024, contributing to the overall revenue growth [47] Market Data and Key Metrics Changes - The Americas accounted for 54% of total ARR, with a growth rate of 29%, while EMEA and Asia-Pacific represented 34% and 12% of ARR, growing 18% and 31% respectively [43] - The company noted strong performance in the US federal sector, with ARR growth in the mid-20% range [31] Company Strategy and Development Direction - Cellebrite aims to migrate 50% of its digital forensics installed base to the Inseyets product suite by the end of 2025, up from 20% at the end of 2024 [25][100] - The company is focused on expanding its cloud and AI capabilities, with cloud-based offerings nearly doubling to 17% of total ARR in 2024 [29] - A new technology and strategy committee has been launched to leverage board members' expertise in driving corporate strategy [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining top-line growth and generating attractive profitability and free cash flow in 2025, despite some modest headwinds from geopolitical changes [12][56] - The company anticipates full-year 2025 revenue to range from $480 million to $490 million, reflecting a 20% to 22% growth over 2024 [57] Other Important Information - Cellebrite achieved FedRAMP-ready status, which is expected to double its Total Addressable Market (TAM) in the federal sector [33][114] - The company plans to expand its workforce by approximately 15% in 2025 [50] Q&A Session Summary Question: Status of CEO search and impact of federal spending uncertainty - Management is optimistic about the CEO search, having interviewed at least a dozen qualified candidates, but no specific timeline for completion was provided [68][70] - Management noted that while there are modest headwinds due to regime changes, they believe these will ultimately lead to opportunities for growth [73][74] Question: Customer pain points and product roadmap - Key customer pain points include the need for efficiency tools and faster case closures, which Cellebrite is addressing through its Inseyets and Pathfinder platforms [79][80] Question: Impact of exiting specific countries - Exiting certain countries is expected to have a minimal impact, contributing less than 2% to revenue in 2024, with improvements in gross retention anticipated [83] Question: C2C penetration and initiatives for 2025 - The company aims to increase C2C penetration from 15% to 50% in 2025, leveraging the connectivity between its offerings [90][91] Question: Federal sector growth and FedRAMP certification - FedRAMP certification is expected to significantly enhance opportunities in the federal sector, potentially doubling the TAM [114] Question: Investigative unit sales strategy - The company is adopting a combined sales approach for the investigative unit, focusing on demand creation and budget awareness [128]

Q SUITS CA February 13, 2025 :: Cellebrite Q4 & FY24 : Cellebrite DISCLAIMER पीढ़ presentation has deen prosesed in Calebication D Liber "Ocencery" jsobly for videormalinde loupposes. Nis not, and should not be easymeri o be porpolete. Nis presen पीढ़ presentable in noi dreeteb ig, or the cebooks for disclibrish to or use ly, any pessor or catility the la stiller or resident in only locally, sale, est of siddition angalation or white would resuire any redeletablin or ücesing with nouslings issussisted this ...

Core Insights - Cellebrite DI Ltd. reported quarterly earnings of $0.10 per share, matching the Zacks Consensus Estimate, but down from $0.11 per share a year ago [1] - The company achieved revenues of $109.05 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 1.11% and up from $93.01 million year-over-year [2] - The stock has gained approximately 13.1% since the beginning of the year, outperforming the S&P 500's gain of 2.9% [3] Earnings Performance - The company has surpassed consensus EPS estimates three out of the last four quarters, with a previous quarter surprise of 27.27% [1] - Current consensus EPS estimate for the upcoming quarter is $0.09, with expected revenues of $107.93 million, and for the current fiscal year, the estimate is $0.44 on revenues of $469.44 million [7] Industry Outlook - The Technology Services industry, to which Cellebrite belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

Financial Performance - Fourth-quarter 2024 revenue reached $109.0 million, a 17% year-over-year increase[1] - Subscription revenue for the fourth quarter was $95.1 million, up 21% year-over-year[3] - Annual Recurring Revenue (ARR) grew 25% to $395.9 million[1] - Full-year 2024 revenue totaled $401.2 million, reflecting a 23% year-over-year increase[8] - Revenue for Q4 2024 reached $109,049,000, a 17.2% increase from $93,013,000 in Q4 2023[27] - Total revenue for Q4 2024 reached $109.049 million, a 17.2% increase from $93.013 million in Q4 2023[31] Profitability Metrics - Adjusted EBITDA for the fourth quarter was $28.8 million, with a margin of 26.4%[3] - Operating income for Q4 2024 was $15,727,000, compared to $14,999,000 in Q4 2023, indicating a 4.9% increase[27] - Net income for Q4 2024 was $19,269,000, a significant recovery from a net loss of $14,647,000 in Q4 2023[27] - The adjusted EBITDA margin for the year ended December 31, 2024, was 24.8%, compared to 19.1% in 2023, showing an improvement of 5.7 percentage points[27] - The company achieved a non-GAAP operating income of $92,119 million for the year 2024, compared to $55,282 million in 2023, indicating a 67% increase[36] - The non-GAAP net income for the year 2024 reached $97,761 million, up from $60,926 million in 2023, which is a 60% increase[38] Cash Flow and Assets - Cash flow from operating activities for the year ended December 31, 2024, was $132,171,000, compared to $102,058,000 in 2023, marking a 29.5% increase[27] - Total assets as of December 31, 2024, amounted to $690,567,000, up from $532,885,000 in 2023, representing a 29.6% growth[28] - The company ended the year with cash and cash equivalents of $191.659 million, stable compared to $189.517 million at the end of 2023[33] Expenses and Investments - Research and development expenses for the year were $98.415 million, a 16.7% increase from $84.386 million in 2023, reflecting ongoing investment in new technologies[31] - Total operating expenses for the year were $281.704 million, up from $238.642 million in 2023, primarily driven by increased R&D and marketing efforts[31] - Share-based compensation for the year 2024 totaled $30,575 million, up from $18,998 million in 2023, representing a 61% increase[38] Future Outlook - For 2025, the company expects ARR between $480 million and $495 million, representing annual growth of 21% to 25%[10] - The first-quarter 2025 revenue expectation is between $107 million and $112 million, with annual growth projected at 19% to 25%[10] - Cellebrite's outlook for 2025 includes plans to advance its market and technology leadership while generating robust free cash flow[26] Product and Technology Developments - Cellebrite's Government Cloud platform received FedRAMP High Ready designation, enhancing its cloud security offerings[7] - Generative Artificial Intelligence capabilities were launched within the Guardian evidence management solution[12] Deferred Revenue - The company reported an increase in deferred revenue of $22.317 million for the year, indicating strong future revenue potential[33]

Company delivers “Rule of 50” Performance in 2024 with 25% ARR growth and 25% adjusted EBITDA margin Fourth-quarter 2024 revenue of $109.0 million grew 17% primarily due to21% growth in subscription revenue ARR grew 25% to $395.9 million Fourth-quarter 2024 adjusted EBITDA of $28.8 million, 26.4% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private ...

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ:CLBT), a global leader in Digital Investigative (DI) solutions for the public and private sectors, announced today that its Cellebrite Government Cloud platform has achieved FedRAMP High Ready designation by the Federal Risk and Authorization Management Program (FedRAMP). This milestone, which marks the initial stage in the compliance process, reinforces Cellebrite's commitment to equipping and empowering its U. ...

Cellebrite (CLBT) is scheduled to report its fourth-quarter 2024 results on Feb. 15, before market open.See Zacks Earnings Calendar to stay ahead of market-making news.The company has an impressive earnings surprise history. It beat the Zacks Consensus Estimate in the trailing four quarters, delivering an average earnings surprise of 42.2%.CLBT’s Q4 ExpectationsThe Zacks Consensus Estimate for Cellebrite’s revenues in the to-be-reported quarter is pegged at $107.9 million, indicating a 16% year-over-year in ...